Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia

摘要: The objective of this study was to evaluate the efficacy and safety pegylated interferon (PEG-IFN) alpha-2a monotherapy in a cohort Chinese haemophilic patients co-infected with human immunodeficiency virus (HIV)/hepatitis C (HCV) undergoing highly active antiretroviral drugs therapy. Twenty-two (n = 22) CD4 lymphocyte counts over 200 cells microL(-1) were treated 180 microg PEG-IFN subcutaneously once week for 48 weeks. HCV load (HCV RNA), HIV (HIV RNA) measured at baseline 4, 12, 24, 72 weeks after initiation anti-HCV Efficacy analysed according status (> or =350 microL(-1)). Significant HCV-RNA decreases (>1 log(10) copies mL(-1)) observed through PEG-INF across both strata. not associated treatment outcomes as evaluated using rapid viral response rate (P 0.655), early 0.387), end-of-treatment 1.000) sustained (SVR, P 0.674). A virological achieved nine (41%), five genotype 2a (83%) four 1b (25%, 0.023). SVR dependent. Eleven required dose reduction alpha-2a. could be considered safe effective option infection haemophilia, particularly resource-limited settings. While higher resulted greater reduction, predictor response.